非小细胞肺癌脑转移免疫检查点抑制剂治疗的研究进展  

Progress of immune checkpoint inhibitors therapy for non-small cell lung cancer with brain metastases

作　　者：黄梅 李燕京[2] 孟庆威[1] Huang Mei;Li Yanjing;Meng Qingwei(Department of Respiratory Medicine,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Gastroenterology,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院呼吸内科,哈尔滨150081 [2]哈尔滨医科大学附属肿瘤医院消化内科,哈尔滨150081

出　　处：《肿瘤研究与临床》2022年第5期390-393,共4页Cancer Research and Clinic

摘　　要：脑转移是非小细胞肺癌(NSCLC)患者的常见并发症,25%~55%的NSCLC患者会发生脑转移,脑转移的发生预示不良预后。传统意义上,放化疗、靶向治疗和手术是NSCLC脑转移的主要治疗选择。近年来随着免疫检查点抑制剂(ICI)的出现,NSCLC脑转移患者生存得到了显著改善。文章将对NSCLC脑转移的ICI治疗研究进展进行综述,以期为患者提供新的治疗策略。Brain metastasis is a common complication of non-small cell lung cancer(NSCLC)patients.About 25%-55%of patients with NSCLC will develop brain metastases,and the occurrence of brain metastasis predicts a poor prognosis.Traditionally,radiotherapy,chemotherapy,targeted therapy and surgery are the main treatment options for NSCLC patients with brain metastases.In recent years,with the emergence of immune checkpoint inhibitors(ICI),the survival of NSCLC patients with brain metastases has been significantly improved.This article reviews the research progress of ICI treatment for NSCLC patients with brain metastases in order to provide new treatment strategies.

关 键 词：癌 非小细胞肺 肿瘤转移 脑肿瘤 免疫抑制剂 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]